非IgM型淋巴浆细胞淋巴瘤的临床与分子特征:REL网络多中心研究
该多中心研究分析了45例非IgM型淋巴浆细胞淋巴瘤(LPL)患者的临床特征、一线治疗及结局,并与华氏巨球蛋白血症(WM)对照组比较。非IgM型LPL女性更多、淋巴结/脾/结外受累更常见,而血清单克隆蛋白和骨髓浸润较少;MYD88突变见于部分患者,5年总生存率84%与WM相似。
要点
- 非IgM型LPL的5年总生存率为84%,与WM患者相似。
核心结论
- 非IgM型LPL与WM临床特征不同,但5年总生存率相似(84%)。
研究设计与样本
- 多中心回顾性研究,纳入45例非IgM型LPL患者,并与WM患者对照组比较。
主要发现
- 等位特异性PCR检测MYD88 L265P突变8/19例;Sanger测序检测CXCR4突变4/17例。
- 靶向NGS(16例)检出MYD88突变7例(44%)、CXCR4突变4例(25%)、KMT2D突变3例(19%)、TP53突变1例(6%)、TRAF3突变1例(6%)。
关键数值与推荐
- 5年总生存率84%。
临床怎么用
- 对非IgM型LPL应关注淋巴结、脾及结外受累的评估。
- 非IgM型LPL治疗可更多采用含蒽环类方案。
- MYD88和CXCR4突变检测有助于分子分型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphoplasmacytic lymphoma (LPL) is usually associated with a serum IgM paraprotein, corresponding to Waldenström's Macroglobulinemia (WM). Cases presenting with IgG or IgA, or without a monoclonal protein are extremely rare. We analyzed clinical characteristics, frontline treatment, and the outcome of 45 patients with non-IgM LPL, and compared them with a control group of WM patients. The median age was similar, with significantly higher prevalence of females in non-IgM LPL, than in WM patients (60% vs 39%, P = .016). Patients with non-IgM LPL more frequently presented with lymphadenopathies (53% vs 15%, P < .001), splenomegaly (22% vs 8%, P = .015) or extranodal involvement (20% vs 8%, P = .05). In non-IgM LPL a serum monoclonal protein and bone marrow infiltration were less common than in WM patients (69% and 84% of cases respectively, P < .001 for both comparisons). The MYD88 (L265P) mutation was found in 8/19 patients using allele-specific polymerase chain reaction. A CXCR4 mutation was found in 4/17 cases using Sanger. In 16 patients we performed targeted next-generation sequencing of genes MYD88, CXCR4, ARID1-A, KMT2D, NOTCH2, TP53, PRDM1, CD79B, TRAF3, MYBBP1A, TNFAIP3. Seven patients (44%) had a MYD88 mutation (S219C in one), four (25%) a CXCR4 mutation, three (19%) a KMT2D mutation, one (6%) a TP53 mutation and one (6%) a TRAF3 mutation. With a median follow-up of 55.7 months, 36 non-IgM LPL patients (80%) were treated. Non-IgM LPL patients received more frequently anthracycline-containing regimens, as compared with WM patients, who mainly received alkylating-based therapies. Five-year overall survival (OS) was 84%, similar to that of WM patients.
引用
- Varettoni M, Boveri E, Zibellini S, et al. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. Am J Hematol. 2019. PMID: 31378966. doi:10.1002/ajh.25600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。